Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299217 | 1.00 | BCHE (0.64) | BCHELMNAPRMT5WDR77 | |
| SCHEMBL2295371 | 1.00 | BCHE (0.64) | BCHELMNAPRMT5WDR77 | |
| SCHEMBL2297276 | 0.92 | BCHE (0.63) | BCHELMNA | |
| SCHEMBL2295136 | 0.92 | BCHE (0.63) | BCHELMNA | |
| SCHEMBL2294352 | 0.87 | MEN1 (0.53) | BCHELMNAPRMT5WDR77 | |
| SCHEMBL2298783 | 0.87 | MEN1 (0.53) | BCHELMNAPRMT5WDR77 | |
| SCHEMBL2297592 | 0.86 | ADRB2 (0.62) | BCHE | |
| SCHEMBL2294984 | 0.86 | ADRB2 (0.62) | BCHE | |
| SCHEMBL324108 | 0.85 | BCHE (0.64) | BCHELMNA | |
| SCHEMBL2078704 | 0.85 | SMN1; SMN2 (0.57) | BCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | claimed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9227960-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2016-01-05 | — | — | US | disclosed |
| CN-103080096-B | Biaryl (thio) morpholine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2015-12-09 | — | — | CN | disclosed |
| CN-102548976-B | (thio) morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LTD. (BS) | 2015-09-09 | — | — | CN | disclosed |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2015-07-09 | — | — | US | disclosed |
| US-9045441-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2015-06-02 | — | — | US | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590954-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| EP-2473490-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | Abbott Healthcare Products B.V. (NL) | 2012-07-11 | — | — | EP | disclosed |
| CN-102548976-A | (Thio) morpholine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS BV | 2012-07-04 | — | — | CN | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| CN-102120741-A | Production method of an optically active compound | MITSUBISHI TANABE PHARMA CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102050820-A | Preparation method of compound with optical activity | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | BCHE 3161/4885LMNA 1879/4885PRMT5 1161/4885 |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | BCHE 3532/4885LMNA 3601/4885PRMT5 2282/4885 |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | BCHE 3510/4885LMNA 3480/4885PRMT5 2351/4885 |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | BCHE 3977/4885LMNA 2046/4885PRMT5 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.